-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, the US FDA announced that it has approved the listing of StrataGraft developed by Mallinckrodt's Stratatech for the treatment of adult patients with deep partial thickness burns
For many patients with deep burns, treatment usually requires removal of the skin from the undamaged part of the body for transplantation
StrataGraft's design mimics natural human skin, including the dermis and fully differentiated epidermis
▲Comparison of the healing effect between StrataGraft transplantation and autograft (photo source: reference [2])
The safety and effectiveness of StrataGraft are based on two randomized clinical studies involving 101 adult burn patients
Note: The original text has been deleted
Reference materials:
[1] FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns.
[2] BARDA contract supports the development of a more effective skin graft to help burn patients after a rad/nuke event.